Olix Logo.jpg
Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China Companies to focus on cardiovascular, metabolic, and other indicationsOliX will receive initial upfront payment of $6.5 million with up to $450 million plus royalties SHANGHAI, China and SUWON,...
Olix Logo.jpg
OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference
September 24, 2021 08:30 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present new...
Olix Logo.jpg
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Investigational Hair Loss Therapeutic, OLX104C
August 12, 2021 09:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received a...
Olix Logo.jpg
OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate
August 04, 2021 09:00 ET | OliX Pharmaceuticals
- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
Olix Logo.jpg
OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit
June 14, 2021 10:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...
Olix Logo.jpg
OliX Pharmaceuticals to Conduct One-on-One Meetings with Potential Partners at BIO Digital 2021 Conference
June 10, 2021 15:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
Olix Logo.jpg
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia
June 09, 2021 10:00 ET | OliX Pharmaceuticals
SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
Olix Logo.jpg
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
June 07, 2021 08:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has...
Olix Logo.jpg
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics
May 24, 2021 08:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
February 10, 2021 17:45 ET | OliX Pharmaceuticals
Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...